MammaPrint Reduces Breast Cancer Overtreatment.
Results from the prospective, randomized phase III MINDACT study indicate that a subset of women with early-stage breast cancer can forego adjuvant chemotherapy. Investigators hope this eventually changes clinical practice, because unnecessary treatment places many women at risk of long-term side effects, such as cardiac toxicity, secondary cancers, and early menopause.